Two published articles on Oncotype DX test addressed the question “Would the patient be willing to use the technology again?”

A multicentre cross-sectional study was performed in the Netherlands using a questionnaire, and supplemented by retrospective medical chart review; in Richman et al. 2011{24} most outcome data are duplicates of those reported in Tzeng et al. 2010 {23}. Of 104 invited women (mainly lymph node-negative), 78 completed the survey and 77 were analysed. Most women (96%, 74/77) reported that they would have the test again if they had to decide today, and 95%, 73/77 would recommend the test to other women (Table 1 in Appendix 4).